Alexandra Shimmings

1 month ago | insights.citeline.com | Alexandra Shimmings

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch PlansThe German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions. Lykke Hinsch Gylvin (Boehringer Ingelheim)

2 months ago | insights.citeline.com | Alexandra Shimmings

Pipeline Growth Slowed In 2024 But Oncology And Neurologicals Held StrongThere was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.

2 months ago | insights.citeline.com | Alexandra Shimmings

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings07 Apr 2025There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.Choppy stock performance could make further biopharma IPOs difficult in 2025 (Shutterstock)

2 months ago | insights.citeline.com | Alexandra Shimmings

Orphans Cling On To Growth Advantage As Market Share Heads Towards 20%It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.

Mar 26, 2025 | insights.citeline.com | Alexandra Shimmings

Cassava At Crossroads As Simufilam Finally Exits, Stage LeftThe Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.